Investor Relations
Objective mood measurement
Our Vision
Earlier, objective detection
Move from subjective screening to measurable biological signals that enable earlier, more accurate intervention.
Continuous, real-world measurement
Replace episodic assessments with longitudinal data that reflects how patients actually function over time.
Integrated diagnosis, therapy, and monitoring
Connect detection, treatment selection, and outcome tracking into one coordinated, data-driven pathway.
What We're Building
Ranvier is developing an integrated patient-facing experience with three core components:
1
Diagnostics
Ranvier measures mood, cognitive function, and neurological risk using objective biological and behavioural signals. We combine multiple biomarkers for early detection and clearer tracking of change over time. By creating a consistent way to measure brain and mood health, we aim to support more accurate understanding and better clinical decisions.
2
Therapy
Ranvier is advancing a late-stage therapy designed to slow the progression of Alzheimer’s and Parkinson’s disease. By combining objective measurement with targeted intervention, we aim to move beyond symptom management toward measurable disease modification in neurodegenerative care.
3
Platform
We combine multiple data into clear, interpretable insights, integrating sensory, biological, and digital inputs, tracking changes longitudinally, and supporting structured decision-making. We use fragmented data to intervene earlier and engage people on their journey of care optimisation.
The Case for Change
Neurological and mental disorders are the leading cause of disability worldwide and represent one of the fastest-growing healthcare cost burdens globally. (WHO Global Burden of Disease (GBD 2019), World Health Organisation, Neurological Disorders Fact Sheets (2023), OECD Health at a Glance - Mental Health Indicators)
Subjective, late diagnosis
Depression and anxiety diagnosis relies primarily on self-reported questionnaires (e.g., PHQ-9, GAD-7) rather than biological markers. Neurodegenerative disease are often diagnosed after significant neuronal loss has already occurred.
Imprecise treatments
Neurodegenerative treatments can cost tens of thousands per patient annually, while antidepressant response rates remain variable, with approximately 30–50% of patients not achieving remission with first-line therapy.
Episodic measuremsnt
Mental health monitoring is typically conducted during brief clinical appointments, limiting longitudinal insight into real-world function and treatment response.
Biomarker science is maturing
Advances in blood-based biomarkers (e.g., p-tau217, p-tau181), retinal imaging, and digital phenotyping are demonstrating increasing predictive validity for neurodegenerative and psychiatric conditions.
Regulators are demanding objective evidence
Regulatory bodies increasingly require validated biomarkers and objective endpoints in CNS trials, particularly in Alzheimer’s and Parkinson’s disease.
Health systems need better stratification and monitoring
High failure rates in CNS drug development (historically >80%) and rising payer scrutiny are driving demand for earlier stratification and measurable treatment response.
Forward Looking Statements
This page contains forward-looking statements regarding Ranvier’s strategy, pipeline, and future development plans. These statements are based on current expectations and assumptions and involve risks and uncertainties. Actual results may differ materially. Ranvier undertakes no obligation to update forward-looking statements except as required by law.
Investor Contact
For investor enquiries, partnership discussion, or further information: